Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases
Related Experiment Video
Updated: Feb 20, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
William L Read1, Sumita Trivedi2, Felicia Williams1
1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Abstract:
•Progestins can produce clinical benefit in a subset of women with metastatic endometrial cancer.•Corticosteroid-related effects of megestrol can cause morbidity over the long term.•Norethindrone is a progestin without corticosteroid side effects.•A switch from megestrol to norethindrone decreased toxicity with continued benefit.•A clinical trial of norethindrone for this population of patients would be welcome.
More Related Videos
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

